Klox Technologies
Klox is a private biomedical technology innovator that targets specific skin and soft tissue conditions by controlling the benefits of fluorescence generated energy to penetrate and manage the skin from within. The unique products we bring to the market stimulate the skin’s own biological processes and repair mechanisms, which demonstrate high safety and efficacy, helping clinicians improve patient outcomes without compromise.
Our technology induces Fluorescence Biomodulation (FB), which has shown to impact cellular signaling pathways in the skin. We research, develop, and commercialize solutions based on our fluorescence-generating technology for a growing and aging population that is seeking more effective and less invasive options to improve their health.
Explore our Technology
Klox products are applied to the skin and activated by LED light for a short exposure period lasting under ten minutes.
Light interacts with light absorbing molecules (LAM) embedded within the Klox gel to generate fluorescent energy.
Klox is a medical device company that transforms lives through its innovative Fluorescence Biomodulation technology. Read more.
Wound Care
Wound care specialists and patients require innovation that can predictably heal chronic wounds. Advanced wound care generates more than $9 billion in costs, driven by difficulties in hard to heal wounds, an aging population and an increasing demand for homecare treatments.
LumiHeal™ is a globally patented wound care solution, supported by scientific evidence (five clinical studies) and a CE mark in Europe.
Partnering
Klox invests in the development, innovation and delivery of launch-ready technology and products. To commercialize our Fluorescence Biomodulation technology, we rely on investment capital and long-term business partners with expertise in our therapeutic categories.
We are offering our high growth LumiHeal™ wound care system and our late-stage Phovia™ veterinary system for strategic partnerships.
Trusted Collaborators
At Klox, we always strive to build and invest in our science, technology, and engineering expertise. To challenge the conventions of the industry, we extend our capabilities by collaborating with leading professionals and cutting-edge scientific facilities, wherever they may be. Our extended network is critical for maintaining vitality and scientific rigor in our mission to bring Fluorescence Biomodulation to patients in need.
News & Events
July 2, 2018
Klox announces positive top-line results from a pivotal study of Phovia™ for the management of Canine Deep Pyoderma – See Full Press Release
June 13, 2018-June 14, 2018
Wound Care from Innovations to Clinical Trials (WCICT) – Edinburgh, United Kingdom
June 4, 2018-June 7, 2018
BIO International Convention – Boston, USA
May 9, 2018-May 11, 2018
The European Wound Management Association (EWMA) – Krakow, Poland
May 2, 2018-May 3, 2018
The Bloom Burton & Co. Healthcare Investor Conference – Toronto, Canada
April 25, 2018-April 29, 2018
The Symposium on Advanced Wound Care Spring (SAWC) – Charlotte, North Carolina
August 25, 2017
Initiated clinical trial on Klox FB Silicone Sheet dressing for post-surgical scar management post elective reconstructive surgery – Montreal, Canada